Sucampo Reports Second Quarter 2017 Financial Results
02 août 2017 06h30 HE
|
Sucampo Pharmaceuticals Inc
Patent Issued for Pipeline Compound VTS-270 for Niemann-Pick Disease Type C1 Diluted EPS Loss of $3.92 Resulting from $186.6M IP R&D Second Quarter Charge Due to Accounting Treatment of Vtesse...